In this webinar, our expert panel of speakers will introduce the new EnSight™ Multimode Plate Reader from PerkinElmer and demonstrate how the unique combination of well-imaging with labeled and label-free detection technologies can produce more reliable readouts and generate more predictive data earlier in the drug discovery process.
As an example, our guest speaker Dr. Philip Gribbon (European ScreeningPort, Hamburg), will discuss the use of the EnSight system in anti-cancer drug discovery, for testing cell viability and proliferation in phenotypic readouts. Dr. Gribbon will present results obtained using EnSight, comparing the use of digital phase-contrast imaging and ATP detection for routine profiling of 4 cancer cell lines against a panel of standard cytotoxic and anti-cancer compounds.
EnSight is the first plate reader to offer cell imaging capabilities in addition to label-free, Alpha and conventional multimode detection technologies. The well-imaging technology enables users to quickly visualize cells and generate data which is intrinsically quantifiable on a per-cell basis. For instance, in complex assays where classification of rare events such as colony formation is important, combining imaging with whole well readouts is now possible. The EnSight system's advantage is its ability to extract physiologically relevant phenotypic parameters using advanced imaging methods and in the same instrument monitor target-based readouts using industry standard multimode detection technologies.
How the EnSight system can help you to generate more predictive data earlier in the drug discovery process
How to improve your data quality and reduce your costs in cell-based assays
How the EnSight system's imaging capabilities make it an ideal instrument for use in anti-cancer drug discovery
A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.